Cargando…
The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease
BACKGROUND: Chronic liver disease (CLD) is usually asymptomatic but earlier detection is critical to permit life-saving interventions for those at risk due to high alcohol consumption and increased body mass index (BMI). The aim of this study was to estimate the association between the Enhanced Live...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158048/ https://www.ncbi.nlm.nih.gov/pubmed/32293289 http://dx.doi.org/10.1186/s12876-020-01251-w |
_version_ | 1783522459402633216 |
---|---|
author | Trembling, Paul M. Apostolidou, Sophia Gentry-Maharaj, Aleksandra Parkes, Julie Ryan, Andy Tanwar, Sudeep Burnell, Matthew Harris, Scott Menon, Usha Rosenberg, William M. |
author_facet | Trembling, Paul M. Apostolidou, Sophia Gentry-Maharaj, Aleksandra Parkes, Julie Ryan, Andy Tanwar, Sudeep Burnell, Matthew Harris, Scott Menon, Usha Rosenberg, William M. |
author_sort | Trembling, Paul M. |
collection | PubMed |
description | BACKGROUND: Chronic liver disease (CLD) is usually asymptomatic but earlier detection is critical to permit life-saving interventions for those at risk due to high alcohol consumption and increased body mass index (BMI). The aim of this study was to estimate the association between the Enhanced Liver Fibrosis (ELF) test and liver-related events (LRE) and its performance in predicting LRE in postmenopausal women with risk factors in a nested case-control study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). METHODS: In a cohort of 95,126 we performed a case-control study measuring ELF in blinded samples from 173 participants with self-reported high alcohol use and / or BMI ≥25 kg/m(2) comprising all 58 cases who developed LRE and 115 controls matched for age, alcohol and BMI who did not develop LRE during median follow-up of 8.5 years. RESULTS: Using Cox regression at an ELF threshold of 10.51 hazard ratios (HR) for LRE were 4.88 (95% confidence interval (CI) 2.37–10.03) (unadjusted model) and 4.62 (95% CI 2.12–10.08) (adjusted for deprivation and self-reported hypertension, heart disease, hypercholesterolaemia and diabetes). At a threshold of 9.8 HR for LRE were 2.21 (95% CI 1.22–3.97) (unadjusted model) and 2.18 (95% CI 1.19–4.01) (adjusted). ELF was evaluated as a time dependent variable by generating time-dependent Cox models; HRs at an ELF threshold of 10.51 were 1.94 (95% CI 1.10–3.39) (unadjusted) and 2.05 (95% CI 1.16–3.64) (adjusted) and at a threshold of 9.8 HRs were 1.85 (95% CI 1.09–3.15) (unadjusted) and 1.80 (95% CI 1.04–3.13) (adjusted). Area under the receiver operating characteristic curve for recruitment ELF predicting LRE was 0.58 (95% CI 0.49–0.68), and for second subsequent ELF 0.61 (95% CI 0.52–0.71). CONCLUSION: This study demonstrates the association between ELF and CLD in postmenopausal women with risk factors for liver disease, creating the opportunity to intervene to reduce liver-related mortality and morbidity. Although larger studies are required, these results demonstrate the potential of ELF as a prognostic tool in health checks in primary care. TRIAL REGISTRATION: This study is nested in UKCTOCS. UKCTOCS is registered as an International Standard Randomised Controlled Trial, number ISRCTN22488978. Registered 06/04/2000. |
format | Online Article Text |
id | pubmed-7158048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71580482020-04-20 The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease Trembling, Paul M. Apostolidou, Sophia Gentry-Maharaj, Aleksandra Parkes, Julie Ryan, Andy Tanwar, Sudeep Burnell, Matthew Harris, Scott Menon, Usha Rosenberg, William M. BMC Gastroenterol Research Article BACKGROUND: Chronic liver disease (CLD) is usually asymptomatic but earlier detection is critical to permit life-saving interventions for those at risk due to high alcohol consumption and increased body mass index (BMI). The aim of this study was to estimate the association between the Enhanced Liver Fibrosis (ELF) test and liver-related events (LRE) and its performance in predicting LRE in postmenopausal women with risk factors in a nested case-control study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). METHODS: In a cohort of 95,126 we performed a case-control study measuring ELF in blinded samples from 173 participants with self-reported high alcohol use and / or BMI ≥25 kg/m(2) comprising all 58 cases who developed LRE and 115 controls matched for age, alcohol and BMI who did not develop LRE during median follow-up of 8.5 years. RESULTS: Using Cox regression at an ELF threshold of 10.51 hazard ratios (HR) for LRE were 4.88 (95% confidence interval (CI) 2.37–10.03) (unadjusted model) and 4.62 (95% CI 2.12–10.08) (adjusted for deprivation and self-reported hypertension, heart disease, hypercholesterolaemia and diabetes). At a threshold of 9.8 HR for LRE were 2.21 (95% CI 1.22–3.97) (unadjusted model) and 2.18 (95% CI 1.19–4.01) (adjusted). ELF was evaluated as a time dependent variable by generating time-dependent Cox models; HRs at an ELF threshold of 10.51 were 1.94 (95% CI 1.10–3.39) (unadjusted) and 2.05 (95% CI 1.16–3.64) (adjusted) and at a threshold of 9.8 HRs were 1.85 (95% CI 1.09–3.15) (unadjusted) and 1.80 (95% CI 1.04–3.13) (adjusted). Area under the receiver operating characteristic curve for recruitment ELF predicting LRE was 0.58 (95% CI 0.49–0.68), and for second subsequent ELF 0.61 (95% CI 0.52–0.71). CONCLUSION: This study demonstrates the association between ELF and CLD in postmenopausal women with risk factors for liver disease, creating the opportunity to intervene to reduce liver-related mortality and morbidity. Although larger studies are required, these results demonstrate the potential of ELF as a prognostic tool in health checks in primary care. TRIAL REGISTRATION: This study is nested in UKCTOCS. UKCTOCS is registered as an International Standard Randomised Controlled Trial, number ISRCTN22488978. Registered 06/04/2000. BioMed Central 2020-04-15 /pmc/articles/PMC7158048/ /pubmed/32293289 http://dx.doi.org/10.1186/s12876-020-01251-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Trembling, Paul M. Apostolidou, Sophia Gentry-Maharaj, Aleksandra Parkes, Julie Ryan, Andy Tanwar, Sudeep Burnell, Matthew Harris, Scott Menon, Usha Rosenberg, William M. The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title | The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title_full | The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title_fullStr | The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title_full_unstemmed | The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title_short | The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
title_sort | enhanced liver fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158048/ https://www.ncbi.nlm.nih.gov/pubmed/32293289 http://dx.doi.org/10.1186/s12876-020-01251-w |
work_keys_str_mv | AT tremblingpaulm theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT apostolidousophia theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT gentrymaharajaleksandra theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT parkesjulie theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT ryanandy theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT tanwarsudeep theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT burnellmatthew theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT harrisscott theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT menonusha theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT rosenbergwilliamm theenhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT tremblingpaulm enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT apostolidousophia enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT gentrymaharajaleksandra enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT parkesjulie enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT ryanandy enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT tanwarsudeep enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT burnellmatthew enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT harrisscott enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT menonusha enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease AT rosenbergwilliamm enhancedliverfibrosistestisassociatedwithliverrelatedoutcomesinpostmenopausalwomenwithriskfactorsforliverdisease |